By the InsightArea Editorial Team
AbbVie reported $17.4 billion in third-quarter 2026 net revenue, up 10.3% from a year earlier. Its immunology portfolio grew even as sales of Humira declined. The reason is visible in the mix: newer products Skyrizi and Rinvoq grew while the older medicine continued to lose sales.
The results released October 30, 2026 illustrate a challenge shared by many pharmaceutical companies: an established product can face competition while the company tries to build new sources of revenue. All dollar figures in this article are US dollars, and the report covers the quarter ended September 30.
For investors, the question is not simply whether one medicine grew. It is how the whole portfolio changes, what the company spends to develop it and what expectations are already reflected in the share price.
What happened to Humira?
AbbVie reported $683 million in global Humira net revenue for the quarter, down 31.2% on a reported basis from a year earlier. A decline in a formerly important product can be significant, but its effect on total company results depends on the size and performance of the rest of the portfolio.
Drug sales can decline for several reasons, including competition after a period of market exclusivity, changes in pricing, reimbursement and prescribing. A company’s reported sales figure reflects its revenue, not a direct count of all patients using a medicine.
It is also important to separate a product’s medical role from its investment performance. A medicine can remain important to patients while its sales decline because of competitive or commercial changes. Conversely, strong sales growth does not by itself establish that one treatment is appropriate for a particular patient.
How did Skyrizi and Rinvoq change the picture?
Skyrizi generated $5.776 billion in global net revenue, up 22.7% on a reported basis. Rinvoq generated $2.706 billion, up 23.9%. AbbVie reported total immunology portfolio revenue of $9.165 billion, up 16.3% on a reported basis.
These figures show why a portfolio-level view matters. Growth in two products can more than offset a decline in another for a given period, but that relationship can change. Each product faces its own competitive, regulatory and commercial risks.
Percentage growth also depends on the starting point. A smaller product can grow rapidly in percentage terms while adding fewer dollars than a larger product with a lower growth rate. Investors can compare both the rate and the change in reported revenue instead of ranking products on percentages alone.
Reported growth includes the effects reflected in the company’s US-dollar accounts. AbbVie also provides operational growth figures at constant exchange rates. These can help readers consider currency effects, but the operational measure is an adjustment and should be read alongside the reported result.
What else contributed to the quarter?
AbbVie reported $3.389 billion in neuroscience portfolio revenue, up 19.4% on a reported basis. Its oncology portfolio generated $1.696 billion, up 0.8%, while the aesthetics portfolio generated $1.176 billion, down 1.4%.
Those different growth rates are a reminder that a company’s total revenue can conceal uneven trends. A strong area can support the overall result while another faces slower growth or declining sales. The divisions also differ in products, competitive environments and potential sensitivity to consumer or healthcare spending.
Investors should be careful with product names that appear in different contexts. AbbVie reported Botox Therapeutic within neuroscience and Botox Cosmetic within aesthetics. Those figures relate to different reported uses and portfolio categories; they should not be combined or compared without checking the company’s definitions.
Why are there two earnings-per-share figures?
AbbVie reported diluted earnings per share of $2.37 under US generally accepted accounting principles and adjusted diluted EPS of $3.82. Adjusted earnings exclude specified items using the company’s stated methodology. The company said both measures included an unfavorable $0.11-per-share impact from acquired in-process research and development and milestone expenses.
The gap between GAAP and adjusted EPS is a reason to read the reconciliation. Adjustments can make individual charges easier to examine, but excluded items can still represent economic costs. Pharmaceutical companies may regularly acquire research programs, so investors should look at the pattern of such spending over time.
Per-share results also depend on the share count as well as total earnings. A change in EPS does not, by itself, reveal whether the business became more profitable because of higher sales, lower expenses, taxes or a change in shares outstanding.
What does the revised guidance say?
AbbVie raised its expected 2026 adjusted diluted EPS range to $13.95–$13.99. The company said that range includes a $0.69-per-share unfavorable impact from acquired research and milestone expenses incurred year to date through the third quarter.
Guidance is management’s forward-looking estimate. Actual results may differ because of product sales, costs, acquisitions, legal or regulatory events and other factors. Investors should compare the eventual full-year figure with the same adjusted definition and review any changes in the items included.
The company also announced a 5.2% dividend increase beginning with the dividend payable in February 2027. A declared or announced dividend policy is not a guarantee of all future payments. Its sustainability depends on cash generation, investment needs, debt and company decisions.
How should investors think about concentration?
Replacing a declining product with growing products can improve the immediate revenue picture while creating a new form of concentration. Skyrizi and Rinvoq together account for a substantial portion of the reported quarter’s sales. That makes their future performance important even though AbbVie has other businesses.
Drug portfolios depend on research and development as well as existing products. Clinical trials can fail, approvals can be delayed and competing treatments can enter a market. An acquisition may add potential candidates but also requires capital and carries integration and development risks.
For an investor holding AbbVie through a healthcare ETF, the effect depends on the fund’s weight in the company and its other holdings. A sector fund can spread company-specific exposure while retaining risks shared across healthcare businesses, including pricing, regulation and clinical outcomes.
What should readers watch next?
Follow portfolio sales in both dollars and percentages, including how quickly established products decline and newer products grow. Compare GAAP and adjusted earnings using the company’s reconciliation, and consider operating cash flow alongside dividends and investment spending.
Finally, separate operating performance from valuation. A company can report strong growth and still be priced for demanding future expectations. Friday’s results show a portfolio in transition; they do not determine what any individual investor should do.
This article is educational and is not personalized investment advice.
Explore the book: 
How to Do Hard Things: The Discomfort Trap
Comments are closed.